Merck & Company Inc (MRK)vsPTC Therapeutics Inc (PTCT)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PTCT
PTC Therapeutics Inc
$66.06
-1.94%
HEALTHCARE · Cap: $5.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 6499% more annual revenue ($66.57B vs $1.01B). MRK leads profitability with a 4.8% profit margin vs -3.8%. PTCT appears more attractively valued with a PEG of 0.81. PTCT earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold36
out of 100
Grade: F
PTCT
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for PTCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Strong operational efficiency at 41.3%
Revenue surging 101.5% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
ROE of -7740.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PTCT
The strongest argument for PTCT centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 101.5% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while PTCT is a hypergrowth play — different risk/reward profiles.
PTCT carries more volatility with a beta of 0.55 — expect wider price swings.
PTCT is growing revenue faster at 101.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PTCT scores higher overall (52/100 vs 36/100) and 101.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?